Tag results:
lymphoid cells
Immunology of Infectious Disease News
Peripheral Immune Phenotypes and T Cell Receptor Repertoire in Pneumocystis Pneumonia in HIV-1 Infected Patients
[Clinical Immunology] Mass cytometry and high-throughput sequencing of the T cell receptor were used to profile the host immune response to HIV-1 and P. jirovecii infection.
Immune Regulation News
HIPK2 Directs Cell Type–Specific Regulation of STAT3 Transcriptional Activity in Th17 Cell Differentiation
[Proceedings of the National Academy of Sciences of the United States of America] The authors reported that in mouse T helper 17 (Th17) cells, Stat3 phosphorylation at serine 727, required for its transcriptional activity, was carried out by homeodomain-interacting protein kinase 2 (HIPK2), a nuclear kinase selectively up-regulated in Th17 cells, but not other Th subtypes that have distinct functions in immunity.
Immune Regulation News
A Peptide Encoded by Pri-miRNA-31 Represses Autoimmunity by Promoting Treg Differentiation
[EMBO Journal] miPEP31 was highly expressed in Foxp3+ Tregs and significantly promoted the differentiation of Tregs without affecting their inhibitory ability.
Cell Therapy News
Characterizing Piggybat- a Transposase for Genetic Modification of T Cells
[Molecular Therapy-Methods & Clinical Development] Researchers utilized the previously described transposase from the little brown bat, designated piggyBat, for production of CD19 specific CAR T cells.
Cell Therapy News
Bioinstructive Implantable Scaffolds for Rapid In Vivo Manufacture and Release of CAR-T Cells
[Nature Biotechnology] The authors described an implantable Multifunctional Alginate Scaffold for T Cell Engineering and Release that streamlined in vivo CAR-T cell manufacturing and reduced processing time to a single day.
Cell Therapy News
A Novel and Efficient CD22 CAR-T Therapy Induced a Robust Antitumor Effect in Relapsed/Refractory Leukemia Patients When Combined with CD19 CAR-T Treatment as a...
[Experimental Hematology & Oncology] Preclinical investigation of the CD22 CAR-T therapy against B cell malignancies was evaluated by co-culturing CD22 CAR-T cells with tumor cell lines or primary blasts from patients in vitro and using a xenograft mouse model in vivo.